Collegium Pharmaceutical Inc

Healthcare · Drug Manufacturers - Specialty & Generic

21.90$ +0.0% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Income Statement

Collegium Pharmaceutical Inc (COLL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 200 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement COLL
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	0.4	1.3	2.2	3.6	12	11	64	73	70	73	75	75	73	74	77	78	79	76	88	83	79	27	84	124	127	130	145	136	137	150	145	145	159	182	178	188	209	205	194	200	808
Cost of Revenue	0.0	0.2	0.4	0.6	0.6	1.1	43	47	46	30	49	49	47	49	38	30	31	32	32	33	33	29	35	71	68	80	67	62	56	55	53	54	63	84	80	80	80	77	76	90	323
Gross Profit	0.4	1.1	1.8	3.0	11	9.7	21	26	24	44	25	26	26	25	39	48	48	44	56	50	46	-1.3	48	52	59	50	77	74	80	95	91	91	97	98	97	108	129	128	117	110	485
Research & Development	3.3	3.3	2.1	2.2	2.1	2.2	2.3	2.2	1.9	2.2	3.0	2.5	2.5	2.4	2.7	2.5	2.1	2.5	2.9	3.5	1.5	1.6	4.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–
Selling, General & Administrative	24	28	23	22	23	25	32	31	33	30	32	29	30	25	31	29	26	114	31	30	31	22	55	41	38	26	53	38	35	26	42	43	62	48	76	74	67	68	86	107	328
Total Operating Expenses	27	29	25	24	25	27	34	34	35	33	35	31	33	27	34	32	29	29	34	34	32	33	59	41	38	38	53	38	35	33	42	43	62	60	76	73	66	69	85	107	327
Operating Income	-26	-28	-23	-21	-13	-18	-13	-7.3	-11	11	-10.0	-5.0	-6.4	-2.4	5.1	17	20	15	21	16	14	-34	-10	11	20	12	25	36	45	62	49	47	35	38	22	35	64	59	32	3.7	159
Interest Expense	0.0	0.0	0.1	0.1	0.2	0.2	5.7	6.2	5.9	2.4	0.2	0.2	0.2	0.2	4.8	8.3	8.1	7.7	5.7	5.4	5.1	4.8	5.8	18	19	21	21	22	21	19	17	16	18	23	21	20	22	105	16	20	162
Pre-Tax Income	-26	-28	-23	-21	-13	-17	-19	-13	-17	9.1	-9.7	-4.7	-6.1	-2.2	0.5	8.3	12	7.3	15	11	9.0	-39	-16	-6.6	1.4	-7.8	-18	18	29	47	37	29	16	17	3.1	17	43	29	19	-14	78
Income Tax Expense	0.0	0.0	-0.2	-0.3	-0.3	-0.4	5.7	6.2	5.9	1.9	-0.3	-0.3	-0.3	0.2	4.6	0.2	0.3	0.3	-0.2	-62	1.0	-14	-2.8	-1.5	1.0	-0.6	-0.1	4.8	8.1	15	8.9	9.5	6.2	4.7	0.7	5.0	12	12	4.2	1.5	30
Net Income	-26	-28	-23	-21	-13	-17	-19	-13	-17	9.1	-9.7	-4.7	-6.1	-2.2	0.5	8.1	11	7.0	16	73	8.0	-25	-13	-5.2	0.5	-7.2	-17	13	21	32	28	20	9.3	13	2.4	12	32	17	14	-15	48
EBITDA	-26	-27	-23	-21	-13	-17	17	26	22	27	-5.6	-0.6	-2.0	1.9	16	34	37	32	38	34	31	-17	9.6	50	58	56	42	78	87	101	89	80	76	96	80	94	122	304	91	71	587

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings